What Jade Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 4 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 185,938 |
| Disposed | 0 | 0 |
| Net activity | +0 | +185,938 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Frohlich Tom | Chief Executive Officer | Feb 12 | Grant / award · A | +78,750 | — | — | 86,331 |
| Bekiroglu Elizabeth | See Remarks | Feb 12 | Grant / award · A | +28,125 | — | — | 28,125 |
| Dahms Bradford D. | Chief Financial Officer | Feb 12 | Grant / award · A | +37,813 | — | — | 37,813 |
| King Andrew James | See Remarks | Feb 12 | Grant / award · A | +41,250 | — | — | 386,113 |
| Fairmount Funds Management Llc | Director | Oct 06 | Grant / award · A | +1,333,126 | $9.14 | +$12.2M | 1,897,677 |
| Frohlich Tom | Chief Executive Officer | May 16 | Open-market buy · P | +6,000 | $7.40 | +$44.4K | 6,000 |
| Ra Capital MANAGEMENT, L.p. | 10% owner | Apr 28 | Other Transaction · J | +1,062,326 | — | — | 1,287,858 |
| Dake Benjamin T | SEE REMARKS | Aug 01 | Exercise / conversion · M | +1,507 | $1.74 | +$2.62K | 14,252 |
| Dake Benjamin T | SEE REMARKS | Jul 31 | Exercise / conversion · M | +11,454 | $1.74 | +$19.9K | 12,745 |
| Ra Capital MANAGEMENT, L.p. | Director | Jun 17 | Open-market buy · P | +928,110 | $1.67 | +$1.55M | 7,893,678 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER | Jun 14 | Open-market sale · S | −10,600 | $25.00 | −$265K | 0 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER | Jun 14 | Exercise / conversion · M | +10,600 | $14.59 | +$155K | 10,600 |
| Eldridge George A | SEE REMARKS | Jun 14 | Open-market sale · S | −15,000 | $25.03 | −$375K | 5,022 |
| Eldridge George A | SEE REMARKS | Jun 14 | Exercise / conversion · M | +15,000 | $2.14 | +$32.1K | 20,022 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | Jun 13 | Open-market sale · S | −6,000 | $24.50 | −$147K | 5,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | Jun 13 | Exercise / conversion · M | +6,000 | $2.14 | +$12.8K | 11,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | May 17 | Open-market sale · S | −86 | $21.86 | −$1.88K | 5,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | May 17 | Open-market sale · S | −3,914 | $21.07 | −$82.5K | 5,688 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | May 17 | Exercise / conversion · M | +4,000 | $2.14 | +$8.56K | 9,602 |
| Noyes Timothy P | CHIEF EXECUTIVE OFFICER | May 16 | Exercise / conversion · M | +10,000 | $2.14 | +$21.4K | 10,000 |
Loading...
